Accelerating early phase development in the UK and Germany
Recent changes in the regulatory environment post-pandemic and the introduction of EU-CTR 536/2014 are making the UK and Germany more attractive to biotech drug developers. In this video, Parexel experts provide an update on recent early-phase regulatory timelines in the UK and Germany, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies.
Also, our thought leaders answer your questions about recent changes with the MHRA and EU-CTR process, approval timelines, and the government’s efforts to make these key regions more attractive for conducting clinical trials.
Parexel Biotech can connect every step of development with you. Our Early Phase services combine clinical pharmacology and regulatory expertise to help you move swiftly and efficiently to the proof of concept milestone. Learn more about our clinical units and integrated Early Phase expertise.
Related Insights
Blog
Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines
Apr 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Related Insights
Blog
Best practices for maximizing early-phase trial efficiency to accelerate regulatory timelines
Apr 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023